immunopathogenesis of several diseases, leading to the identification of relevant molecules in inflammatory processes. The progress of molecular biological techniques has allowed to modify these compounds and the majority of antibodies in use are chimeric, humanized or fully human.
Infliximab is a chimeric IgG 1 monoclonal antibody binding tumor necrosis factor (TNF)-u, that in recent years has revolutionised the treatment of many chronic inflammatory diseases such as rheumatoid arthritis (RA), spondiloarthritis (SpA), psoriasis and Crohn's disease, and it has been proposed for the treatment of other conditions resistant to the traditional therapies such as Churg-Strauss' syndrome, Behcet's disease, Wegener's granulomatosis and autoimmune uveitis. However, infliximab therapy can be complicated by a variety of ADRs (3) . As expected, the immune system usually responds to this chimeric monoclonal antibody as foreign antigen by producing antibodies towards different sites of the molecule, especially against the murine part (anti-mouse antibodies). Acute infusion reactions occur during, or within 24 hours after infusion, whereas a delayed reaction is defined as any adverse reaction that occurs from 24 hours to 14 days after administration (4) . Although the mechanisms of these reactions are not clearly defined, it has been proposed that such reactions may be the consequence of the immune response against infliximab with the development of antibodies to infliximab itself (5) .
In this paper we analyze the adverse events recorded in our case series of patients affected by different chronic inflammatory disorders, and we examine the relationship between the features of the reaction and the infliximab dose, the rate of infusion, the efficacy of pre-treatment and of other potential risk factors.
MATERIALS AND METHODS

Subjects
A total of49 patients (23 female; 26 male; age range 18-65 years) with different diseases (16 rheumatoid arthritis, 12 Behcet's disease, II seronegative spondyloarthritis, 6 Wegener's granulomatosis, 3 Churg-Strauss' syndrome, I Cogan's disease) treated with infliximab atthe Immunology Unit of Biomedicine Department, were included in the study. These patients were treated with infliximab as conventional immunosuppressive drugs failed to control disease. According to the recommendations, infliximab was always associated with methotrexate (MTX) in patients suffering from RA. On enrolment, patients had never been administered biological agents.
Infliximab infusions
Patients were infused with 3 or 5 mg/Kg infliximab over a 2 h period at 0, 2, 6 and 14 weeks and every two months thereafter. Infliximab was administered at an average infusion rate of 100 ml/h (30' at 80 ml/h and 90' at 120 ml/h). Pre-treatment with hydroxyzine (25 mg) and prednisone (25 mg) was carried out 30' prior to infusion. One patient was also pre-treated with paracetamol after the third infusion reaction (see below). Patients were monitored throughout the duration of treatment and for 2 h after infusion. Vital signs including blood pressure, heart rate, and oxygen saturation were monitored before and during the infusion.
Infusion reactions
Infusion reactions were defined as adverse events occurring during the treatment or within 14 days after infusion. In particular, acute infusion reactions were defined if they occurred during, or within 24 hours after infusion; whereas a delayed reaction was defined as any adverse reaction that occurred from 24 hours to 14 days after administration (4) . Systemic reactions were classified as mild, moderate or severe according to the grading system for generalized hypersensitivity reaction proposed by Brown et al. (6) .
Statistical analysis
A X 2 test was used to analyse differences between patient groups, and p<0.05 value was considered as significant.
RESULTS
Prevalence and severity ofreactions to infliximab
Taken as a whole, the enrolled patients received a total of 709 infliximab infusions at doses of 3 or 5 mglkg, each patient receiving a mean of 16.4±11.2 infusions. We observed 11 infusion-related reactions out of 709 infusions (1.5 %)·performed in 6 of49 patients (12.2%); two patients who had an initial mild infusion reaction were re-treated but developed a total of five subsequent reactions (Table I) . We observed only acute infusion reactions occurring within the first hour of treatment, and mostly characterized by shivers (5/11; 45%), respiratory distress (3/11; 27.2%) and sudden flushing ( patients who were not pre-treated (p=NS). Thus, the frequency and severity of infliximab reactions were not related to different kinds of pre-treatment (Table  II) . 27.2%). We classified our reactions as mild (6/11; 54.6%), moderate (2/11; 18.1%) and severe (3/11; 27.3%), according to the grading system proposed by Brown and co-workers for hypersensitivity reactions (Table I) (6) .
Effects of pre-treatment on the prevalence of infliximab reactions
504 out of 709 infusions (71%) were preceded by pre-treatment with prednisone (25 mg) and/or hydroxizine (25 mg). In the last year, prior to infliximab treatment we pre-treated all patients as a general prophylaxis of hypersensitivity reactions, independently of each individual's history. In 17 patients we performed 205 infusions without pretreatment, even though most of them (14/17; 82.3%) were receiving daily prednisone (average dose 8±2.1 mg/die). Only 56 of 205 infusions (27.3%) were performed in 2 out of 17 patients with no concomitant steroid pre-treatment or daily therapy. Eight (1.58%) reactions occurred in all infusions performed in pretreated patients and 3 infusion reactions occurred in
Effect of dose and therapy discontinuation on the prevalence ofinfliximab reactions
We performed 554 infusions at 3 mg/Kg (78.1%) and 155 infusions at 5 mg/Kg (21.8%). No significant difference in the frequency of reactions between infusions performed at 3 or 5 mg/Kg was observed (data not shown).
Thereafter, we examined the relationship between infusion-related reactions to infliximab and the individual course of treatment. In contrast with other previous studies (3), we observed no reactions during the first infusion, whereas all reactions occurred between the 2 nd and the 9 th infusion with a cluster around the 5 th and the 6 th infusion. Nine out of 49 (18.3 %) patients discontinued the course of treatment for an average period of 5.8±2.8 (mean±SD) months (range 3-8.6 months), mainly due to severe infections. Of note, a significant increase of the prevalence of reactions in patients who had discontinued treatment was seen. Indeed, 4 out of 6 (66.6%) reactive patients displayed the reaction at the beginning of the second course of therapy after a period of discontinuation, whereas only 5 out of 43 (11.6 %) unreactive patients displayed a period of treatment interruption (p<0.025) ( Fig. 1 ). unreactive patients showed ANA positivity. Thus, no increase of prevalence of reactions in ANA-positive patients was found. Since the cohort of our patients was quite heterogeneous from a clinical point of view, we analysed the prevalence of infliximab reactions on the basis of the disease. We observed a significantly higher incidence ofreactions in patients suffering from RA (3.4%) than in patients suffering from seronegative SpA or vasculitis (0.44%) (p<O.OO 1) (Fig. 2) . However, the proportion ofANApositive patients was similar in RA and non-RA patients (data not shown). Focusing on RA patients, we observed a higher incidence ofANA positivity in reactive (75%) than in unreactive (33%) RA patients. However, this data does not reach significance, likely reflecting the problem of statistical power. By contrast, the analysis of autoantibody profile, showed a broader pattern, being characterized also by an anti-extractable nuclear antigen (ENA) and by organ-specific autoantibodies in RA patients with infliximab reactions, compared to unreactive subjects (p<O.OO 1) ( Fig. 3) .
Relationship between atopy, drug hypersensitivity and infliximab reactions
We analysed the presence of risk factors for infliximab reactions. We investigated whether the atopic condition and a history ofprevious (last 3 years) ADRs and episodes of urticaria and/or angioedema could affect the incidence of infliximab reactions. One out of 6 (16.6%) patients who experienced an infliximab infusion reaction, had allergic symptoms (allergic rhinitis and conjunctivitis) and a previous ADR to non-steroidal anti-inflammatory drugs (Table I) . A similar prevalence of atopy and previous
Relationship between infusion reactions and concomitant immunosuppressive regimen
Twenty-three out of 49 patients (46.9%) received MTX (mean dose 12.5±2.5 mg/week) and 40 patients (81.6%) received prednisone (mean dose 1O±6.5 mg/die). Of the patients who experienced reactions, 4 received a concomitant therapy with MTX and prednisone whereas 2 received a daily dose of prednisone alone, for better control of the disease. Thus, no relationship between frequency, type and severity of infusion reaction and immunosuppressive therapy was seen. ' #-10
Relationship between autoantibody titre and infliximab reactions
Data from the literature show that baseline antinuclear antibody (ANA) positivity may be a predictive factor for infliximab reaction (7) . We evaluated the presence of autoantibodies in 45 of 49 patients at the beginning of the treatment; 15 out of 45 patients (33.3%) and 3 out of 6 patients (50%) who experienced infliximab reactions, displayed ANA-positivity. On the other hand, 12 of39 (30.7%) A larger proportion of patients with infliximab reaction (33.3%) rather than unreactive (14.8%) patients referred previous episodes of urticarial angioedema, but this difference failed to reach statistical significancy (Fig. 4) . Thus, in our case series, atopy, drug hypersensitivity, and previous episodes of urticaria/angioedema were not related to an increased risk of infliximab reactions.
DISCUSSION
The safety of infliximab therapy currently represents an important field of research considering its growing clinical application. Our data show a lower prevalence of infliximab reactions (1.5%) compared to other studies reporting an average incidence of 8-20% (3, (8) (9) (10) , although some authors refer a lower one (2%) (11). In our case we observed only immediate reactions, all of them during the first hour oftreatment and mostly characterized by mild or moderate severity. The low incidence of immediate infusion reactions in our patients could be related to concomitant clinical procedures performed, such as pre-treatment regimens, low rate of infusion and chronic immunosuppressive therapy.
In this paper we tried to correlate infliximab reactions with several parameters. As an inverse dose-immunogenicity relationship has been reported (12), we addressed this issue in our study. As recently reported in other studies (10), we did not observe differences in the prevalence of infusion reactions in patients treated with 3 versus 5 mg/Kg. Thereafter we addressed our attention to the timing of the infusion reactions. The infliximab reactions mainly occurred at the 5 th and 6 th infusion, but none during the first course of treatment, thus infliximab therapy must be considered as a safe treatment after this critical point, even if we observed two reactions at the 9 th and 14 th infusion, although of mild grade, and in one patient who experienced multiple reactions. This study also reports that the safety of infliximab infusion is transiently reduced in patients who have discontinued therapy. Although the underlying mechanism of this phenomenon is not clear, it is of particular interest from a clinical point of view, since many patients have to stop therapy transiently for concomitant infections or other clinical conditions that counterindicate infliximab infusion. In agreement with our data, are the results obtained in adults and children with Crohn's disease who experienced severe systemic reactions when a distant reinfusion interval was attempted (13) .
Regarding the possible pathogenetic mechanisms, our results, in agreement with other previous reports (14) (15) , suggest that the majority of acute reactions is not IgE-mediated and that atopy does not represent a risk factor for the development of infliximab infusion reactions. However, it is relevant to stress that normal total serum IgE levels, as observed in our reactive patients, does not absolutely rule out the existence of low levels of specific IgE antibodies and thus, of a biological allergic background able to drive an infusion reaction. Furthermore, the observation that most infusion reactions are responsive to slowing the infusion rate (16) and that they do not consistently occur with every infusion, even without prophylaxis, suggests that further mechanisms other than type I hypersensitivity are involved. Data from animal models support this hypothesis since protein-induced fatal anaphylaxis can occur in IgE-KO-mice. Moreover, antigenspecific IgG antibodies may trigger a fatal reaction in normal as well as in mast cell-KO mice (17) (18) (19) . Likewise, it is well-known that cells different from mast cells, such as platelets, release mediators able to increase vascular permeability (i.e. serotonin), as well as chemotactic factors (20) . Similarly, three patients who experienced acute systemic reactions did not show elevated serum tryptase levels within 120 minutes from the reaction, suggesting a mast cell-independent mechanism. Clinical trials showed that up to 68% of the infliximab-treated patients developed IgG antibodies to this molecule and that they are associated with immediate infusion reactions (11, 21) . IgG antibodies can directly activate immune cells (i.e. by Fc-IgG receptors) or the complement system via immune complexes leading to clinical signs and symptoms not different from type I hypersensitivity reactions (18) .
It is well known that immunosuppressive drugs such as MTX or hydrocortisone pre-treatment before each infusion (5, 22) may be protective against the development of antibodies to infliximab (ATI). We did not perform ATI analysis in our patients, but we did not display a protective role for immunosuppressive therapy and/or pre-treatment in our study. It is therefore very difficult to assess the true effect of each procedure, since most patients were receiving both immunosuppressive therapy and pre-treatment regimens. Nor did we find a relationship between the type and severity of infusion reactions with concomitant immunosuppressive therapy. Nevertheless, it may be hypothesised that the absence of delayed reactions in our case studies could be related to a protective effect of the daily administration of prednisone and/or immunosuppressive therapy for the control of disease activity.
Increased levels of autoantibodies have been commonly reported in patients treated with anti-TNFa agents (23) (24) . The presence ofautoantibodies can be the expression of the infliximab-induced immune response, likely involving an increased production of cytokines leading to polyclonal B cell proliferation and autoantibody production (25) . We did not find a significant increase of ANA positivity in patients with infusion reactions, thus suggesting that ANA positivity is not "per se" a predictive factor for adverse reactions in infliximab treatment. By contrast, we found an increased prevalence of infliximab reactions in patients suffering from RA compared to patients suffering from SpA and vasculitis, independently from the baseline ANA status. It may be hypothesized that the cellular and molecular mechanisms underlying the disease affecting patients could represent a background favouring the mechanisms of the reactions toward biological agents. Even if much more effort to evaluate the relationship between the type of disease and infliximab reactions should be made, we are in favor of infliximab treatment when it is proposed.
In conclusion, in our experience infliximab treatment is rarely complicated by adverse reactions which, more importantly, are usually mild. Some good clinical practices such as a low rate of infusion and pre-treatment with antihistamine and prednisone in all patients, may reduce the frequency and severity of immediate reactions and avoid delayed ones. Moreover, we think that avoidance of long intervals between infusions may represent a further useful strategy to reduce the frequency of infliximab reactions and to increase its safety.
